This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Levosulpiride is indicated to treat dyspepsia, symptoms of Meniere's syndrome, and second line in the treatment of drug-induced nausea and vomiting.

Generic Name
Levosulpiride
DrugBank Accession Number
DB16021
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 341.43
Monoisotopic: 341.140927407
Chemical Formula
C15H23N3O4S
Synonyms
  • Levosulpirida
  • Levosulpiride
  • Levosulpiridum
  • S-(-)-Sulpiride

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Levosulpiride.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Levosulpiride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Levosulpiride.
AclidiniumLevosulpiride may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levosulpiride.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levosulpiride.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Levosulpiride.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Levosulpiride.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Levosulpiride.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levosulpiride.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
LEPRIT® ENZIMATICOGRAGEASLevosulpiride (25 mg) + Pancrelipase (150 mg) + Simethicone (80 mg)Tablet, coatedOralMANUFACTURERA MUNDIAL FARMACEUTICA S.A.2010-12-15Not applicableColombia flag

Categories

ATC Codes
N05AL07 — Levosulpiride
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
JTG7R315LK
CAS number
23672-07-3
InChI Key
BGRJTUBHPOOWDU-NSHDSACASA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
IUPAC Name
N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCC[C@H]1CNC(=O)C1=CC(=CC=C1OC)S(N)(=O)=O

References

General References
  1. AIFA Product Information: LEVOSULPIRIDE FERRER (levosulpiride) oral [Link]
ChemSpider
599749
ChEBI
64119
ChEMBL
CHEMBL267044
ZINC
ZINC000000057008
Wikipedia
Levosulpiride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentDiabetic Macular Edema (DME) / Diabetic Retinopathy (DR)1
2, 3CompletedTreatmentAgitation1
1CompletedBasic ScienceDyspepsia1
Not AvailableCompletedTreatmentDyspepsia / Helicobacter Pylori Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Solution / dropsOral
Tablet, delayed releaseOral
SolutionOral2.5 g
SolutionOral25 mg
SolutionOral2500 mg
TabletOral25 mg
Solution / dropsOral25 MG/ML
Tablet, coatedOral
Tablet, coatedOral25 mg
TabletOral100 MG
TabletOral50 MG
Injection, solutionParenteral12.5 MG/ML
Injection, solutionParenteral25 MG/ML
Injection, solutionIntravenous; Parenteral50 MG/2ML
Injection, solutionParenteral25 MG/2ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability35.59 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 14, 2020 14:09 / Updated at May 05, 2021 20:32